Atossa Therapeutics announces AACR poster presentation on (Z)-endoxifen in McCune-Albright syndrome

Reuters2026/07/21 12:32

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Atossa Therapeutics released a July 21, 2026 update on preclinical (Z)-endoxifen data in McCune-Albright syndrome presented at an AACR rare cancers meeting.
The poster outlined a proposed dual mechanism targeting estrogen receptor signaling, PKC-β/AKT pathways to address peripheral precocious puberty linked to the disorder.
Atossa flagged the findings as supporting further evaluation of (Z)-endoxifen in the indication, with potential relevance to estrogen-driven cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607210830PR_NEWS_USPR_____SF08684) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Atossa Therapeutics announces AACR poster presentation on (Z)-endoxifen in McCune-Albright syndrome

You may also like

Crypto prices